Sayanag K, et al. - Investigators assessed 30 eyes of 28 subjects to compare the progression of chorioretinal atrophy (CRA) between intravitreal injections of ranibizumab (IVR) and aflibercept (IVA) in the eyes with myopic choroidal neovascularization (mCNV). They observed improvement in the best-corrected visual acuity (BCVA) from 0.44 to 0.26, 0.19, 0.20, and 0.17 after 1, 3, 6, and 12 months, respectively with no significant difference in CRA progression between the two medicines. At 1 year, the foveal choroid was recorded significantly thinner in aflibercept-treated eyes as compared to ranibizumab-treated eyes. They suggested that the CNV location might prognosticate CRA succession after anti-vascular endothelial growth factor treatment for mCNV.